Clinical trial Recruiting at 1 site Interventional

Using brain stimulation to treat apathy in Alzheimer's disease

Official title: Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)

Run by Sunnybrook Health Sciences Centre · NCT05561205 · Data updated 2026-11-12

This study is testing whether a brain stimulation treatment can help reduce feelings of apathy in people with Alzheimer's disease, including those who are taking a medication for it.

More Dementia trials

Quick facts

Study typeInterventional
SexAll
Enrollment10 (estimated)
SponsorSunnybrook Health Sciences Centre
Academic / other
Locations1 site (Toronto, Ontario)
StatusRecruiting
StartedFebruary 9, 2023
Main results expectedDecember 1, 2026
Study endsDecember 1, 2026
Registry record updatedApril 13, 2026
Trial IDNCT05561205 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals diagnosed with Alzheimer's disease who have experienced apathy for at least four weeks.

Probably not a fit

Patients currently experiencing a major depressive episode or those with certain neurological conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for apathy in individuals with Alzheimer's disease. Participants will include those receiving methylphenidate, a medication known to improve apathy, and those not on any medication. The study aims to assess the effectiveness of rTMS in alleviating symptoms of apathy, which is a common and debilitating condition in dementia. The trial will include individuals diagnosed with major neurocognitive disorders who have experienced apathy for at least four weeks.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with Alzheimer's disease by reducing apathy.

How similar studies have gone: Other studies have shown promise in using rTMS for various neurological conditions, suggesting potential for success in this novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* mild or major neurocognitive disorder OR mild behavioural impairment
* Apathy for at least 4 weeks
* Stable dose of medication (\>4 weeks) that may affect cognition or behaviour
* Care partner who spends at least 10 hours a week with the subject

Exclusion Criteria:

* Current major depressive episode
* Agitation, delusions, hallucination
* Medical contraindications to rTMS
* Currently taking an amphetamine product
* Central nervous system abnormalities, Tourette's syndrome, or motor tics
* Current participation in another clinical trial

Where it's running

  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.